



CLINICAL RESEARCH

Heart rate and use of β -blockers in Mexican stable outpatients with coronary artery disease



Marco Antonio Alcocer-Gamba^{a,b,c,*}, Carlos Martínez-Sánchez^{c,d},
Juan Verdejo-Paris^{c,d}, Roberto Ferrari^e, Kim Fox^f, Nicola Greenlaw^g,
Gabriel Steg Philippe^{f,h,i,j}, por los investigadores CLARIFY

^a Instituto de Corazón de Querétaro, Querétaro, Mexico

^b Coordinador Nacional CLARIFY, Mexico

^c Sociedad Mexicana de Cardiología

^d Instituto Nacional de Cardiología "Ignacio Chávez", Cd México, Mexico

^e Department of Cardiology and LTTA Centre, University Hospital of Ferrara and Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy

^f NHLI Imperial College, ICMS, Royal Brompton Hospital, London, United Kingdom

^g University of Glasgow, Glasgow, United Kingdom

^h INSERM, U698, Paris, France

ⁱ Université Paris Diderot, Paris, France

^j AP-HP, Hôpital Bichat, Paris, France

Received 7 February 2014; accepted 16 January 2015

KEYWORDS

Heart rate;
 β -Blockers;
Stable coronary
artery disease;
Mexico

Abstract

Objective: To evaluate the use of β -blockers and to monitor heart rate in Mexican patients with coronary artery disease.

Methods: CLARIFY is an outpatients registry with stable CAD. A total of 33,283 patients from 45 countries were enrolled between November 2009 and July 2010 from which 1342 were Mexican patients.

Results: The mean HR pulse was 70 bpm (beats per minute). Patients in Mexico were compared with the remaining global CLARIFY population. Patients in Mexico had a higher incidence of acute myocardial infarction and percutaneous coronary intervention, and lower incidence of revascularization surgery compared with the remaining CLARIFY population. More often, Mexican patients presented with diabetes, but less often hypertension and stroke. These patients were split into three mutually exclusive groups of HR ≤ 60 ($N = 263$), HR 61–69 ($N = 356$) and HR ≥ 70 ($N = 722$). Patients with elevated HR had a higher incidence of diabetes and higher diastolic blood pressure on average than those with controlled HR. Regarding the use of β -blockers,

* Corresponding author at: Prol. Privada zaraoza no. 16-b 2 piso col centro cp. 76000, Mexico. Tel.: +52 2162745; fax: +52 2164922.
E-mail address: Marco.alcocerg@gmail.com (M.A. Alcocer-Gamba).

they were used in 63.3% of patients, 2.7% showed intolerance or contraindication to treatment to monitor heart rate, and ivabradine was used in 2.3%. Out of approximately 849 patients receiving treatment of β -blockers, 52.1% had ≥ 70 bpm HR.

Conclusions: In a large proportion of Mexican patients with stable coronary disease the HR remain elevated, >70 bpm, even with the use of β -blockers; this requires further attention.

© 2014 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. All rights reserved.

PALABRAS CLAVE

Frecuencia cardíaca;
Beta bloqueadores;
Enfermedad
coronaria estable;
México

Ritmo cardíaco y empleo de beta bloqueadores en pacientes ambulatorios estables mexicanos con enfermedad arterial coronaria

Resumen

Objetivo: Evaluar en pacientes con enfermedad coronaria estable, el uso de beta-bloqueadores y la frecuencia cardíaca.

Métodos: El estudio CLARIFY es un registro internacional de pacientes ambulatorios con enfermedad coronaria estable. Se incluyeron un total de 33,283 pacientes de 45 países durante el periodo de noviembre de 2009 a julio de 2010; de estos, 1342 pacientes fueron mexicanos.

Resultados: La frecuencia cardíaca (FC) media fue de 70 lpm (latidos por minuto). Se compararon los pacientes mexicanos con la población internacional incluida en el estudio. Los primeros tuvieron una mayor incidencia de infarto agudo del miocardio e intervención coronaria percutánea y menor incidencia de cirugía de revascularización comparado con la población mundial. La población Mexicana presentó mayor incidencia de diabetes pero menor incidencia de hipertensión y EVC. A estos se les dividió en tres grupos mutuamente excluyentes $FC \leq 60$ (N = 263), $FC 61-69$ (N = 356) y $FC \geq 70$ (N = 722). Los pacientes con FC elevada presentaron mayor incidencia de diabetes, y un registro mayor de tensión arterial sistólica comparado con aquellos con FC controlada. Respecto al uso de beta bloqueadores estos se administraron a 63.3% de los pacientes; el 2.7% mostró intolerancia o contraindicación al tratamiento con estos fármacos. Se administró ivabradina al 2.3% de los pacientes. De los 849 pacientes que recibieron tratamiento con beta-bloqueadores, el 52.1% mostró FC de ≥ 70 lpm.

Conclusiones: La gran mayoría de los pacientes mexicanos con enfermedad coronaria estable la FC permaneció elevada, >70 bpm, aun con el uso de beta bloqueadores.

© 2014 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Todos los derechos reservados.

Introduction

Coronary artery disease (CAD) is the worldwide leading cause of death,^{1,2} yet there is a paucity of data regarding the clinical characteristics and management of outpatients with stable CAD. Most of the available data come from patients admitted for acute coronary syndromes or treated with percutaneous coronary intervention (PCI). In addition, data often come from Europe or North America. The prospective observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry was initiated to improve our knowledge regarding patients with stable CAD from a broader geographic perspective.³ The main objectives of the registry are to define contemporary stable CAD outpatients in terms of their demographic characteristics, clinical profiles, management, and outcomes; identify gaps between evidence-based recommendations and treatment; and investigate long-term prognostic determinants in this population.

Heart rate (HR) is a primary determinant of myocardial ischemia, and has been established as a prognostic factor

in patients with CAD⁴⁻⁸ and in those with congestive heart failure (CHF).⁹ It has also been correlated with the risk of future coronary events.^{4,10} The elevation of the HR in healthy patients usually indicates a modification between sympathetic and parasympathetic system because of the raise of the sympathetic tone or decrease of the parasympathetic tone.¹¹ β -Blockers have many other actions, such as reducing the HR. Current data show that HR reduction with pure bradycardic agents is also associated with clinical benefits, such as prevention of angina and reduction of myocardial ischemia.¹²⁻¹⁴ Little is known about the actual HR obtained in clinical practice, even in patients receiving HR-lowering treatments such as β -blockers. Similarly, there is a paucity of data in the management of patients with elevated HR in CAD related with the use of β -blockers and other HR-lowering agents.

The analysis describes the use of a large contemporary database stemming from a broad geographic representation; Mexican patients were compared to other global patients, specifically for the stable Mexican outpatients with CAD, the HR achieved, the use of β -blockers, and

described the determinants of elevated HR in the Mexican population.

Methods

CLARIFY is an ongoing international, prospective, observational, longitudinal cohort study in stable CAD outpatients, with 5 years of follow-up. Patients eligible for enrollment were outpatients with stable CAD proven by a history of at least one of the following: documented myocardial infarction (>3 months ago); coronary stenosis >50% in coronary angiography; chest pain with myocardial ischemia proven by stress electrocardiogram and stress echocardiography, or myocardial imaging; and history of coronary artery bypass graft surgery or percutaneous coronary intervention (performed >3 months ago).

Patients hospitalized for cardiovascular disease within the previous 3 months (including for revascularization), patients for whom revascularization was planned, and patients with conditions expected to hamper participation or 5-year follow-up (e.g. limited cooperation or legal capacity, serious non-cardiovascular disease, conditions limiting life expectancy, or severe cardiovascular disease [such as advanced heart failure, severe valve disease, history of valve repair/replacement, etc.]) were excluded from participating in the study. Information collected at baseline included: (a) demographics; (b) risk factors and lifestyle; (c) medical history and current symptoms; (d) physical examination: heart rate determined by pulse palpation; (e) interpretation of last electrocardiogram taken within the previous 6 months; (f) lab report: fasting blood glucose, hemoglobin A1c (HbA1c), cholesterol, triglycerides, serum creatinine, and hemoglobin, if available; (g) current chronic medical treatments taken by the patient for more than 7 days prior to the entry in the registry. Data are collected and analyzed at an independent academic statistics center at the Robertson Centre for Biostatistics, University of Glasgow, UK. The study is being performed in accordance with the principles of the Declaration of Helsinki and was approved by the National Research Ethics Service, Isle of Wight, Portsmouth and Southeast Hampshire Research Ethics Committee, UK. Approval was also obtained from all 45 participating countries, in accordance with local regulations before recruitment of the first participant. All patients signed a written informed consent to participate, in accordance with national and local guidelines. The CLARIFY Registry was evaluated by the ethics committee and registered in the ISRCTN registry of clinical trials with the number ISRCTN43070564.

Data are summarized using number (percentage) for categorical variables and mean (standard deviation) or median [lower quartile, upper quartile] for the continuous variables, depending on the distribution of the data. Comparisons between the Mexican population and the rest of the CLARIFY population were tested using Pearson's chi-square test or Fisher's exact test for the categorical variables, and Analysis of Variance (ANOVA) or Kruskal–Wallis test for the continuous variables. Depending on the distribution of the data, these methods were also used to compare differences between heart rate groups of ≤ 60 bpm, 61–69 bpm and ≥ 70 bpm, within the Mexican population.

The cut-off of 70 bpm to determine an elevated HR for the multivariable model was selected based on the results of several studies showing that it is an important prognostic threshold across a variety of patient populations.^{4,12,15–17} All clinical baseline variables were considered for entry into the model as predictors of HR ≥ 70 bpm and univariate models for each were produced. The use of HR-lowering medications was considered to be the most important treatment variable, and so this was the only treatment predictor included in the analyses. The multivariable model was then built using a stepwise selection method applied to the remaining significant univariate predictors, with the use of HR-lowering medications being forced into the model.

Results

We included a total of 33,283 patients worldwide, Mexico recruited 1342 patients; however, the heart rate was the only one recorded in 1341 patients. The standard deviation (SD) of HR of total CLARIFY patients was 10.62; Mexican patients have a SD of 9.70. The information collected is summarized in Table 1. The average age was 64 years, 76.0% were men. The median body mass index was 27; the median recorded for abdominal circumference was 94 cm. Significant differences were observed in the labor status of patients worldwide compared to Mexico, finding a 26.9% of patients withdrawn in Mexico, corresponding to 56.3% of the registered in the rest of the world. We documented 6.1% of active smokers at the time of inclusion, 49.8% with a history of smoking at some point in their lives and 44.1% never smoked. The mean systolic blood pressure was 125 mmHg, while the diastolic was 75 mmHg.

Regarding clinical history, in Mexico there was increased incidence of diabetes mellitus type 2 (37.3%), acute myocardial infarction (64.1%) and percutaneous coronary intervention (69.8%) compared to those reported worldwide. In contrast there was a higher incidence of heart failure worldwide at 4.7% (Mexico 3.5%), CABG 23.7% (Mexico 15.9%), stroke 4.1% (Mexico 1.7%), atrial flutter/fibrillation 7.2% (Mexico 2.9%) and dyslipidemia 75.4% (Mexico 62.3%).

Referring to the presence of angina in Mexico we recorded 106 patients divided into four groups depending on the classification of the Canadian Cardiovascular Society Class I documenting 42 patients, 42 in Class II, 21 in Class III and 1 in Class IV. The same methodology was used for recording heart failure symptoms according to the NYHA classification; 1268 were patients without heart failure symptoms, 63 were NYHA II, 10 were NYHA III and LVEF was also determined by finding a mean of 52.6%.

In Mexico there were 894 patients with non-invasive tests for myocardial ischemia and 229 with evidence of presence of myocardial ischemia. Angiographically we determined stenosis >50% in the left main artery in 4.9% patients, in the left anterior descending artery in 63.2% patients, in the circumflex in 30.6% patients and in the right coronary artery in 40.1% patients; 5.7% showed no significant stenosis and 14.3% did not have a record of coronary angiography.

Medication use is summarized in Table 2. Antihypertensives usage in the Mexican population (1342) was reported in 65.7% of the population with ACEI/ARB, 19.2% used nitrates, and calcium antagonists were used by 23.2% of

Table 1 Demographic data characteristics of the study population classified according to Mexico vs. rest of global data.

Parameter	Total (N = 33,283)	Mexico (N = 1342)	Other global data (N = 31,941)	p-Value
Age	64.15 (10.48)	64.38 (11.32)	64.14 (10.44)	.4123
Gender	25,761 (77.49)	1018 (75.97)	24,743 (77.55)	.1751
Body mass index	27.3 [24.8, 30.3]	27 [24.9, 29.7]	27.3 [24.8, 30.4]	.0230
Waist circumference (cm)	96.52 [88, 105]	94 [86.36, 102]	97 [88, 105]	<.0001
Myocardial infarction	19,849 (59.7)	859 (64.06)	18,990 (59.52)	.0009
PCI	19,506 (58.67)	935 (69.78)	18,571 (58.2)	<.0001
CABG	7784 (23.41)	213 (15.88)	7571 (23.73)	<.0001
Aortic abdominal aneurysm	505 (1.52)	11 (0.82)	494 (1.55)	*
Carotid disease	2486 (7.48)	27 (2.01)	2459 (7.71)	<.0001
Internal cardiac defibrillator	414 (1.25)	8 (0.6)	406 (1.27)	*
Pacemaker	796 (2.39)	55 (4.1)	741 (2.32)	<.0001
Transient ischemic attack	1017 (3.06)	23 (1.72)	994 (3.12)	.0035
Hospitalization for CHF	1552 (4.67)	47 (3.5)	1505 (4.72)	.0394
Stroke	1327 (3.99)	23 (1.72)	1304 (4.09)	<.0001
Atrial fibrillation/flutter	2328 (7)	39 (2.91)	2289 (7.17)	<.0001
Asthma/COPD	2453 (7.38)	42 (3.13)	2411 (7.56)	<.0001
Treated hypertension	23,591 (70.96)	900 (67.11)	22,691 (71.12)	.0016
Diabetes	9696 (29.16)	500 (37.29)	9196 (28.82)	<.0001
Dyslipidemia	24,889 (74.86)	835 (62.27)	24,054 (75.39)	<.0001
Peripheral arterial disease	3255 (9.79)	66 (4.92)	3189 (9.99)	<.0001
Smoking status	4126 (12.41)	82 (6.11)	4044 (12.67)	<.0001
Previous smoking	15,093 (45.4)	668 (49.81)	14,425 (45.21)	
Non-smoker	14,029 (42.2)	591 (44.07)	13,438 (42.12)	
Any angina	7315 (22)	106 (7.9)	7209 (22.6)	<.0001
Angina and CCS class				<.0001
No angina	25,930 (78.01)	1235 (92.1)	24,695 (77.41)	
CCS Class I	2091 (6.29)	42 (3.13)	2049 (6.42)	
CCS Class II	3888 (11.7)	42 (3.13)	3846 (12.06)	
CCS Class III	1254 (3.77)	21 (1.57)	1233 (3.87)	
CCS Class IV	78 (0.23)	1 (0.07)	77 (0.24)	
CHF symptoms including NYHA class				<.0001
No CHF	28,298 (85.13)	1268 (94.56)	27,030 (84.73)	
NYHA II	4135 (12.44)	63 (4.7)	4072 (12.76)	
NYHA III	808 (2.43)	10 (0.75)	798 (2.5)	
HbA1c (%)	6.84 (2.03)	7.15 (1.59)	6.84 (2.04)	.0762
Creatinine (mmol/L)	0.088 [0.076, 0.102]	0.088 [0.08, 0.106]	0.088 [0.076, 0.102]	.0003
Hemoglobin (mmol/L)	8.69 [8.07, 9.31]	9.06 [8.19, 9.74]	8.69 [8.07, 9.31]	<.0001
Fasting blood glucose (mmol/L)	5.7 [5.1, 6.6]	5.8 [5.2, 6.9]	5.7 [5.1, 6.6]	.0057
Total cholesterol (mmol/L)	4.3 [3.7, 5]	4.2 [3.5, 5.2]	4.3 [3.7, 5]	.1461
HDL (mmol/L)	1.14 [0.96, 1.37]	0.99 [0.86, 1.17]	1.14 [0.97, 1.38]	<.0001
LDL (mmol/L)	2.37 [1.9, 2.94]	2.39 [1.82, 3.02]	2.37 [1.9, 2.94]	.9327
Fasting triglycerides (mmol/L)	1.4 [1, 1.9]	1.6 [1.2, 2.3]	1.4 [1, 1.9]	<.0001
Heart rate (palpation)	68.29 (10.62)	69.93 (9.7)	68.22 (10.65)	<.0001
ECG heart rate (bpm)	67.18 (11.44)	68.1 (10.78)	67.14 (11.47)	.0127
SBP (mmHg)	131 (16.66)	125.2 (16.54)	131.24 (16.62)	<.0001
DBP (mmHg)	77.24 (9.97)	75.37 (9.93)	77.32 (9.96)	<.0001

Information provided is number (percentage) for categorical variables and mean (SD) or median [lower quartile, upper quartile] for the continuous variables depending on the distribution of the data.

* p-Value is not computable.

the population. Referring to antiplatelet therapy 1243 patients were taking aspirin, 631 thienopyridine and 119 different antiplatelet therapies. The use of lipid-lowering medications was found in 1176 patients. In Mexico the use of

β -blockers was present in 849 patients (63.3%), symptoms of intolerance to β -blockers in 36 patients (2.7%), and ivabradine was used in 31 patients (2.3%). The worldwide records for the same data yielded the following results: use of

Table 2 Medication data of the study population classified according to Mexico vs. rest of global data.

Parameter	Total (N = 33,283)	Mexico (N = 1342)	Other global data (N = 31,941)	p-Value
Aspirin	29,144 (87.68)	1243 (92.83)	27,901 (87.46)	<.0001
Thienopyridine	9036 (27.22)	631 (47.3)	8405 (26.38)	<.0001
β-Blockers	24,984 (75.16)	849 (63.31)	24,135 (75.65)	<.0001
Symptoms indicative of intolerance or contraindication to β-blockers	4797 (14.43)	36 (2.68)	4761 (14.93)	<.0001
Ivabradine	3268 (9.83)	31 (2.31)	3237 (10.15)	<.0001
Calcium antagonists	9059 (27.25)	311 (23.19)	8748 (27.42)	.0006
Verapamil or Diltiazem	1933 (5.82)	82 (6.11)	1851 (5.8)	.6325
Digoxin and derivatives	838 (2.52)	95 (7.08)	743 (2.33)	<.0001
Amiodarone/Dronedaron	972 (2.92)	69 (5.15)	903 (2.83)	<.0001

β-blockers in 75.6%, symptoms of intolerance to β-blockers in 14.93%, and use of ivabradine in 10.1%, showing marked increase in these parameters globally compared to Mexico.

Heart rate was determined by pulse palpation with a mean of 69.9 bpm in the Mexican population and 68.2 bpm in the rest of the CLARIFY population ($p < .0001$), while ECG-derived HR was 68.1 bpm in the Mexican population and 67.1 bpm in the rest of the CLARIFY population ($p = .127$). Of the Mexican patients with ECG information, 882 patients had sinus rhythm, 12 fibrillation/atrial flutter and 18 tachycardia.

Mexican patients were split into three mutually exclusive categories using baseline pulse palpation, HR ≤ 60 ($N = 263$), HR 61–69 ($N = 356$) and HR ≥ 70 ($N = 722$) (Table 3). There were some important, significant differences between the HR subgroups: patients with higher heart rates had higher BMI and more incidence of diabetes. On average, the systolic and diastolic blood pressures were also higher in the group with the highest heart rates. Regarding the use of drugs the group HR ≥ 70 bpm had a significantly greater use of ivabradine (3.5%) compared with the HR ≤ 60 (1.5); higher heart rates corresponded to lower use of β-blockers (61.2% in HR ≥ 70 compared to 68.1% in HR ≤ 60), although this was not statistically significant.

The population was also divided depending on the use of β-blockers. Depending on their use in 849 patients, we analyzed the characteristics of this population; patients receiving β-blockers were significantly younger (mean 63.6 years) compared to those not taking β-blockers (mean 65.8 years), and had higher incidence of hypertension (70.3% compared to 61.6%) and any kind of angina (9.7% compared to 4.9%) (data not shown).

The multivariable analysis for the determinants of elevated heart rate in the Mexican population showed that patients with diabetes, increased BMI and increased diastolic blood pressure were at an increased odds of elevated heart rate, while those with a family history of premature CAD were at slightly reduced odds of increased heart rate (Table 4).

Discussion

The analysis of the results provided a description of the Mexican population compared to the rest of the CLARIFY population. The records indicate a mean age of 64 years, with a high incidence of patients outside the international goals of BMI and waist circumference. Cigarette consumption at any time of life was present in over 50% of the study population, also the Mexican population showed a higher incidence of diabetes and myocardial infarction.

Regarding the labor status of Mexico compared to the world, it showed that Mexico had a withdrawal rate corresponding to half of registered worldwide. We also found that the Mexican population with coronary artery disease is significantly less active compared with that recorded worldwide (data not shown).

In the Mexican population, the average heart rate was 69.9 bpm, and although 63% of the population received treatment with β-blockers, only 19.6% of the population had an HR ≤ 60 bpm, and even within the population with the use of β-blockers, 52% had HR ≥ 70 ; likewise those patients with symptoms of angina only, 22.6%, achieved HR ≤ 60 bpm even though the guidelines for stable angina recommended HR: 55–60 bpm in angina patients treated with β-blockers. By multivariable analysis, many independent predictors of HR ≥ 70 were found, many of which are markers of poor health status. In contrast with this results there are several publications that describe the HR with cardiovascular mortality in healthy populations. In the British Regional Heart Study¹⁸ the authors observed that in individuals without evidence of previous cardiovascular disease there was a significant association between HR and the rate of all the fatal and the non-fatal coronary events, the risk was specially elevated in individuals that has a HR > 90 , the raise of the risk was five times higher than the male that presented HR < 60 bpm. The Paris Prospective Study I¹⁹ showed in the multivariable analysis that the HR was related with sudden death and myocardial infarction. The CASTEL²⁰ study found a higher mortality with HR > 80 . In the Chicago studies²¹

Table 3 Characteristics of the Mexico population classified according to resting heart rate.

Parameter	Total with heart rate (N=1341)	HR (based on palpation) ≤ 60 bpm (N=263)	HR (based on palpation) 61–69 bpm (N=356)	HR (based on palpation) ≥ 70 bpm (N=722)	p-Value
Age	64.39 (11.31)	64.77 (11.2)	64.2 (11.68)	64.34 (11.17)	.8195
Gender	1018 (75.97)	209 (79.47)	269 (75.56)	540 (74.9)	.3246
Body mass index	27 [24.9, 29.7]	26.4 [24.5, 29.1]	26.8 [24.8, 29.7]	27.3 [25, 30.1]	.0181
Waist circumference (cm)	94 [86.36, 102]	93 [86, 102]	95 [87, 102]	95 [86.36, 103]	.2587
Does the patient live alone?	80 (5.97)	15 (5.7)	18 (5.06)	47 (6.52)	.6220
Myocardial infarction	859 (64.06)	174 (66.16)	221 (62.08)	464 (64.27)	.5701
PCI	935 (69.78)	188 (71.48)	245 (69.01)	502 (69.53)	.7859
CABG	213 (15.88)	43 (16.35)	55 (15.45)	115 (15.93)	.9541
Aortic abdominal aneurysm	11 (0.82)	3 (1.14)	1 (0.28)	7 (0.97)	.4285
Carotid disease	27 (2.01)	8 (3.04)	7 (1.97)	12 (1.66)	.3934
Internal cardiac defibrillator	8 (0.6)	1 (0.38)	2 (0.56)	5 (0.69)	1.0000
Pacemaker	55 (4.1)	7 (2.66)	15 (4.21)	33 (4.57)	.4062
Transient ischemic attack	23 (1.72)	7 (2.66)	5 (1.4)	11 (1.52)	.4151
Hospitalization for CHF	47 (3.5)	9 (3.42)	10 (2.81)	28 (3.88)	.6662
Current or previous clinical trial participation	90 (6.71)	22 (8.37)	33 (9.27)	35 (4.85)	.0118
Stroke	23 (1.72)	3 (1.14)	6 (1.69)	14 (1.94)	.6937
Atrial fibrillation/flutter	39 (2.91)	6 (2.28)	11 (3.09)	22 (3.05)	.7958
Asthma/COPD	42 (3.13)	11 (4.18)	8 (2.25)	23 (3.19)	.3902
Family history of premature CAD	328 (24.46)	72 (27.38)	98 (27.53)	158 (21.88)	.0603
Treated hypertension	900 (67.11)	171 (65.02)	231 (64.89)	498 (68.98)	.2929
Diabetes	500 (37.29)	70 (26.62)	116 (32.58)	314 (43.49)	<.0001
Dyslipidemia	835 (62.27)	160 (60.84)	221 (62.08)	454 (62.88)	.8394
Angina and CCS class					*
No angina	1235 (92.1)	239 (90.87)	331 (92.98)	665 (92.11)	
CCS Class I	42 (3.13)	12 (4.56)	11 (3.09)	19 (2.63)	
CCS Class II	42 (3.13)	9 (3.42)	11 (3.09)	22 (3.05)	
CCS Class III	21 (1.57)	3 (1.14)	3 (0.84)	15 (2.08)	
CCS Class IV	1 (0.07)	0 (0)	0 (0)	1 (0.14)	
No CHF	1268 (94.56)	247 (93.92)	342 (96.07)	679 (94.04)	.2781
NYHA Class II	63 (4.7)	14 (5.32)	14 (3.93)	35 (4.85)	
NYHA Class III	10 (0.75)	2 (0.76)	0 (0)	8 (1.11)	

Information provided is number (percentage) for categorical variables and mean (SD) or median [lower quartile, upper quartile] for continuous variables depending on the distribution of the data.

* p-Value is not computable.

were observed that HR was a risk factor for coronary mortality, in young males and in middle aged men and women. In the French population Benetos et al.²² found that HR was a risk factor for non-cardiovascular mortality in both genders. The CASS study investigated the relationship between HR and mortality in patients with stable coronary artery disease⁴ and found that the total mortality, the cardiovascular mortality and cardiovascular rehospitalisation were

associated with the increase in the HR. Patients with a HR baseline ≥ 83 bpm had a total mortality and a higher cardiovascular mortality, after adjusting for multiple variables, when compared with the reference group. These epidemiological data have been reinforced by findings of clinical studies that had shown that HR reduction by drugs such as β -blockers improve prognosis in patients with acute myocardial infarction¹⁵ or heart failure,¹⁶ and it is a fundamental

Table 4 Multivariable logistic regression results for elevated heart rate using a stepwise selection model.

Variable	Odds ratio (95% confidence interval)	p-Value
DBP (per 10 mmHg)	1.26 (1.13, 1.41)	<.0001
Diabetes	1.79 (1.43, 2.26)	<.0001
Family history of premature CAD	0.70 (0.54, 0.91)	.0074
BMI (per 2 kg/m ²)	1.059 (1.001, 1.120)	.0457
Taking any HR-lowering drugs	0.94 (0.73, 1.21)	.6513

part of the beneficial effect of these drugs on the prognosis. In conclusion, the clinical benefits of β -blockers in patients with CAD are well established, particularly the reduction of cardiovascular events in survivors of myocardial infarction.¹⁷ The subjunctive analysis of the BEAUTIFUL study suggests that HR reduction can prevent coronary events.^{23,24} Although the database indicates the impact of the HR in the prognosis in CAD, and the potential benefits of lowering the HR, we found in our study an elevated heart rate, based on the multiple studies mentioned before the Mexican population had a very vulnerable cardiovascular situation. The data of Mexican mortality will be available when the CLARIFY study will be completed in 2015.

Conclusions

A large proportion of patients had an elevated heart rate, even among patients receiving β -blockers, a high percentage that handles HR ≥ 70 , indicating a likely inaccurate dose. The study data were obtained from a random sample from a group of cardiologists, that not necessarily represent the reality of the rest of the patients seen by other physicians. Even though this study reveals that there are multiple potential barriers to more widespread use of β -blockers at appropriate doses to achieve adequate HR control, such as inadequate knowledge of evidence or treatment goals by clinicians access to care and reimbursement, comorbidities that represent contraindications or decrease tolerance to β -blockers and their side effects, and marketing efforts for other agents. Few of the patients not receiving β -blockers are intolerant to these drugs or had conditions that contraindicate its use. Therefore there is a potential for improving HR control rational use of β -blocker and other heart rate lowering medications such as ivabradine, which can be used together. Is very important to sensitize physicians about the importance of the therapeutic heart rate goal that the patients should have after a cardiovascular event. Specially if it is associated with myocardial damage and heart failure then it is necessary to insist on the use of β -blockers in optimum dose, alone or in combination with selective channel blocking drugs such as ivabradine. This drug is a suitable alternative to β -blockers for an adequate chronotropic control with the benefits of reducing cardiovascular events as has been reported in other previous studies.

Funding

No endorsement of any kind received to conduct this study/article.

Conflict of interest

None declared.

References

- Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. *Lancet*. 1997;349:1269–76.
- Anderson GF, Chu E. Expanding priorities – confronting chronic disease in countries with low income. *N Engl J Med*. 2007;356:209–11.
- Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. *Eur Heart J*. 2009;11 Suppl. D:D13–8.
- Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. *Eur Heart J*. 2005;26:967–74.
- Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. *Am J Cardiol*. 1990;65:547–53.
- Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/trandolapril Study (INVEST). *Eur Heart J*. 2008;29:1327–34.
- Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. *J Am Coll Cardiol*. 2007;50:823–30.
- Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. *Lancet*. 2008;372:817–21.
- Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. *Lancet*. 2010;376:886–94.
- Hsia J, Larson JC, Ockene JK, et al. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. *BMJ*. 2009;338:b219.
- Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. *Circulation*. 1971;44:413–8.
- Tardif JC, Ponikowski P, Kahan T, et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. *Eur Heart J*. 2009;30:540–8.
- Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. *Circulation*. 2003;107:817–23.
- Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. *Eur Heart J*. 2005;26:2529–36.
- Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. *Am J Cardiol*. 1986;57:F43–9.

16. Kjekshus JK, Gullestad L. Heart rate as a therapeutic target in heart failure. *Eur Heart J*. 1999;1 Suppl. H:H64–9.
17. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*. 1999;318:1730–7.
18. Shaper AG, Wannamethee G, Macfarlane PW, et al. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. *Br Heart J*. 1993;70:49–55.
19. Jouven X, Desnos M, Guerot C, et al. Predicting sudden death in the population: the Paris Prospective Study I. *Circulation*. 1999;99:1978–83.
20. Palatini P, Casiglia E, Julius S, et al. High heart rate: a risk factor for cardiovascular death in elderly men. *Arch Intern Med*. 1999;159:585–92.
21. Greenland P, Daviglus ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. *Am J Epidemiol*. 1999;149:853–62.
22. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. *Hypertension*. 1999;33:44–52.
23. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;372:807–16.
24. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. *Eur Heart J*. 2009;30:2337–45.